Atorvastatin-esomeprazole — Competitive Intelligence Brief

Atorvastatin-esomeprazole (Atorvastatin-esomeprazole) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin + proton pump inhibitor combination. Area: Cardiovascular.

marketed Statin + proton pump inhibitor combination HMG-CoA reductase; H+/K+-ATPase Cardiovascular Small molecule

Target snapshot

Atorvastatin-esomeprazole (Atorvastatin-esomeprazole) — Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec. This combination drug lowers cholesterol by inhibiting HMG-CoA reductase (atorvastatin) while reducing gastric acid secretion by blocking the proton pump (esomeprazole).

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atorvastatin-esomeprazole TARGET	Atorvastatin-esomeprazole	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Statin + proton pump inhibitor combination	HMG-CoA reductase; H+/K+-ATPase
Rosuvastatin-omeprazole	Rosuvastatin-omeprazole	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Statin + proton pump inhibitor combination	HMG-CoA reductase (rosuvastatin); H+/K+-ATPase (omeprazole)
Rosuvastatin-pantoprazole	Rosuvastatin-pantoprazole	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Statin + proton pump inhibitor combination	HMG-CoA reductase (rosuvastatin); H+/K+-ATPase (pantoprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Statin + proton pump inhibitor combination class)

1. Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec · 3 drugs in this class